Home›Trial›NCT04905693
NCT04905693Phase 3ENROLLING BY INVITATION

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Study Summary

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.

Conditions
Idiopathic Pulmonary FibrosisInterstitial Lung DiseaseProgressive Pulmonary Fibrosis
Interventions / Drugs
Inhaled TreprostinilTreprostinil Ultrasonic Nebulizer
View on ClinicalTrials.gov ↗
Sponsor
UTHR
United Therapeutics
Pulmonary
D35/100
Study Details
Enrollment1850 participants
Primary Completion—
Lead SponsorUnited Therapeutics
Data Retrieved2026-04-11 04:30:42.432941+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 1,850 participants
Sponsor Catalyst Profile

United Therapeutics (UTHR) is the sponsoring company for this trial. BiotechSign currently grades this company D (35/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

UTHR Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.